Zoledronic Acid Monohydrate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Zoledronic Acid Monohydrate |
| DrugBank ID | DB00399 |
| Brand Names (EU) | Zoledronic acid medac |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.56% |
Approved Indication (EMA)
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bone Paget disease | 99.56% | DL |
| 2 | HIV infectious disease | 93.95% | DL |
| 3 | obsolete familial combined hyperlipidemia | 93.51% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 93.08% | DL |
| 5 | biotin metabolic disease | 92.88% | DL |
| 6 | feline acquired immunodeficiency syndrome | 91.04% | DL |
| 7 | simian immunodeficiency virus infection | 91.04% | DL |
| 8 | vitamin deficiency disorder | 90.31% | DL |
| 9 | postmenopausal osteoporosis | 90.13% | DL |
| 10 | Worth syndrome | 89.89% | DL |
| 11 | succinyl-CoA:3-ketoacid CoA transferase deficiency | 89.84% | DL |
| 12 | autosomal dominant neovascular inflammatory vitreoretinopathy | 89.35% | DL |
| 13 | hypoglycemia | 89.23% | DL |
| 14 | pregnancy associated osteoporosis | 88.17% | DL |
| 15 | juvenile Paget disease | 87.66% | DL |
| 16 | cholelithiasis | 85.58% | DL |
| 17 | osteomesopyknosis | 83.58% | DL |
| 18 | Paget disease of bone | 83.35% | DL |
| 19 | palmar fibromatosis | 79.75% | DL |
| 20 | homozygous familial hypercholesterolemia | 79.49% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.